SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Equipment >

Cytosorbents Corporation (CTSO)

CTSO RSS Feed
Add CTSO Price Alert      Hide Sticky   Hide Intro
Moderator: orangecat, dr_lowenstein, dah174174
Search This Board: 
Last Post: 10/20/2017 12:39:01 PM - Followers: 184 - Board type: Free - Posts Today: 4

About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immunotherapy company specializing in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. The company’s flagship product, CytoSorb®, is approved in the European Union with distribution in 39 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death and cost of treatment are extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 14,000 human treatments to date.

CytoSorbents’ blood purification technologies are based on advanced, biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead, approximately the size of a grain of salt, contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies from blood. These beads are synthesized at CytoSorbents’ ISO 13485 certified manufacturing facility in New Jersey. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others.

CytoSorb®

CytoSorb® is approved for sale in all 28 countries of the European Union (E.U.) as an extracorporeal cytokine adsorber, designed to control deadly systemic inflammation by reducing excessive cytokines, bacterial toxins, and many other factors from blood that “fuel the fire” of inflammation. Left unchecked, this uncontrolled inflammation can lead to organ injury, organ failure, and in many cases, death of the patient. The blood purification cartridge can be used with most kinds of extracorporeal blood pumps including standard hemodialysis machines, continuous renal replacement (CRRT) machines, heart-lung machines, and extracorporeal membrane oxygenation (ECMO) machines, in any situation where cytokines are elevated. This includes a diverse range of conditions where excessive cytokines and other inflammatory toxins are driving a potentially dangerous inflammatory response. These include acute critical illnesses such as sepsis and infection, burn injury, trauma, acute respiratory distress syndrome, severe acute pancreatitis, liver failure, influenza, cytokine release syndrome in CAR T-cell immunotherapy, and complications of cardiac surgery, as well as in other more chronic diseases such as cancer, cancer cachexia, autoimmune diseases, and others. CytoSorb® is also being used intra-operatively during open heart surgery in a bypass circuit in a heart-lung machine to pre-emptively reduce inflammatory mediators such as cytokines, activated complement, and plasma free hemoglobin that are generated during the surgery and can lead to post-operative inflammation and organ failure. CytoSorb® has been used in more than 14,000 human treatments to date and have been credited with saving many lives.

With registration, CytoSorb® can also be sold outside of the E.U. in countries that accept European medical device approval. CytoSorb® is being sold directly in Germany, Austria and Switzerland, and marketed through distributors in the United Kingdom, Italy, Spain, Portugal, the Netherlands, the Middle East (including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain, Oman, Yemen, Iraq, Iran, and Jordan), Israel, Turkey, Russia, Australia, New Zealand, Vietnam, and many other countries.

Our strategic partner Fresenius Medical Care, the largest dialysis company in the world, is currently distributing CytoSorb® in France, Norway, Finland, Sweden, Denmark and Poland for critical care applications. Terumo Cardiovascular, a global leader in cardiac and vascular surgery, has also partnered with us to exclusively distribute CytoSorb® for cardiac surgery applications in France, Norway, Sweden, Finland, Denmark, and Iceland. CytoSorb® is currently also being sold in India, Sri Lanka, and select emerging markets through our strategic partner, Biocon Ltd, India’s largest biopharmaceutical company.

There are more than 55 investigator-initiated studies in various stages of process in Europe and Asia using CytoSorb® in a wide variety of applications, with more than a third enrolling patients, and with a number already completed. In addition, the International CytoSorb® Registry has been established to collect and analyze treatment data from all over the world, and is being independently managed by the Center of Clinical Studies at the University of Jena, Germany.

The company is currently completing its 40-patient randomized, controlled, U.S. based REFRESH (REduction of FREe Hemoglobin) I cardiac surgery safety and feasibility trial, using CytoSorb® intra-operatively during elective, non-emergent complex cardiac surgery. If successful, the trial would be the basis of a pivotal REFRESH 2 trial, intended to achieve registration and approval of CytoSorb® in the U.S. for the application of cardiac surgery. The company is also conducting a 30-patient randomized controlled trial in patients with trauma and rhabdomyolysis, funded by the U.S. Air Force.

HemoDefend

HemoDefend™ is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of blood products. The HemoDefend technology utilizes the Company’s polymer bead technology to remove many substances, such as antibodies, free hemoglobin, potassium, and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

The Future of Blood Purification is Now

CytoSorb® and HemoDefend™ are just two of a number of different resins the Company has designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy drugs during treatment of cancer with high dose regional chemotherapy, removal of IV contrast, treatment of drug intoxication, and others. Additional information is available in the Investor Relations section.

CytoSorbents and its technology has garnered more than $18 million in support from the U.S. Government. DARPA, or the Defense Advanced Research Projects Agency, as part of its “Dialysis-Like Therapeutics” program to treat sepsis, awarded CytoSorbents a $3.8 million five year contract to develop cytokine and toxin binders for the program. CytoSorbents collaborates with groups such as Battelle Laboratories, Harvard’s Wyss Institute, NxStage Medical (NASDAQ: NXTM), Massachusetts Institute of Technology, and others in this program. CytoSorbents was also awarded $1.65 million by the U.S. Army in a Phase I, Phase II and Phase II Enhancement SBIR contract to develop its blood purification technologies to treat burn injury and trauma. The U.S. Air Force is also funding an FDA-approved, 30-patient randomized controlled human pilot study using CytoSorb® to treat trauma patients with rhabdomyolysis that has begun. CytoSorbents has also been awarded $1.7 million in Phase I and II SBIR contracts from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) and US Special Operations Command (USSOCOM) to further develop its HemoDefend™ technology for blood transfusions.

CytoSorbents operates through its wholly-owned subsidiary, CytoSorbents Medical Inc. (fka CytoSorbents Inc.), and conducts its European business through its wholly-owned subsidiary, CytoSorbents Europe GmbH. CytoSorbents Corporation converted from a Nevada Corporation to a Delaware Corporation in December 2014.

 

SureTrader
Interactive Brokers Advertisement
CTSO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTSO News: Securities Registration: Employee Benefit Plan (s-8) 09/26/2017 06:04:46 AM
CTSO News: Current Report Filing (8-k) 08/09/2017 06:06:53 AM
CTSO News: Quarterly Report (10-q) 08/07/2017 04:14:03 PM
CTSO News: Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Sol... 08/02/2017 07:00:00 AM
CTSO News: Current Report Filing (8-k) 07/06/2017 05:22:56 PM
PostSubject
#10086   What about PR company, how much money wasted slappie 10/20/17 12:39:01 PM
#10085   These investment conferences are paid vacations for Chanie, slappie 10/20/17 12:38:07 PM
#10084   The cases are "cherry picked" to show doctors biotech48 10/20/17 09:37:55 AM
#10083   As foreseen this Meeting in San Francisco has mikesmith999945 10/20/17 01:16:15 AM
#10082   Amen to that. Cherry picked case studies pearsby09 10/19/17 09:43:02 PM
#10081   How many of these investment conferences has chanie coldterdinvestor 10/19/17 04:03:14 PM
#10080   Of course institutional investors always immediately invest in orangecat 10/19/17 03:52:50 PM
#10079   Looks like yesterdays investment conference got the old coldterdinvestor 10/19/17 03:08:07 PM
#10078   Kite Cart T cell Therapy got FDA approval yesterday. berthabluefish1 10/19/17 02:08:13 PM
#10077   CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis[/ techxen 10/19/17 09:44:57 AM
#10075   From the Bio Presentation today.The New Germany berthabluefish1 10/18/17 11:04:56 PM
#10074   Liked the part about Dr.June and the last berthabluefish1 10/18/17 10:59:36 PM
#10073   This company already has an FDA approved left vinovista 10/18/17 10:05:42 PM
#10068   Do you think the hospital that hit the orangecat 10/18/17 08:46:51 PM
#10066   The trend is your friend DebitsAndCredits 10/18/17 06:38:13 PM
#10065   Interesting. Very small test. Hope we Canes16 10/18/17 04:38:02 PM
#10064   Agree... Fresenius Medical Opens Manufacturing Plant in Malaysia Good Sport 10/18/17 03:37:04 PM
#10063   Looks like bot trading started at 11am and vinovista 10/18/17 02:23:47 PM
#10062   Dies anyone have any idea how much Fresnius, slappie 10/18/17 02:06:53 PM
#10061   What announcement? orangecat 10/18/17 01:57:47 PM
#10060   After today’s very neutral announcement, we as shareholders mikesmith999945 10/18/17 01:35:44 PM
#10059   I did a quick comparison against the previous orangecat 10/18/17 09:40:24 AM
#10058   http://cytosorbents.com/wp-content/uploads/2017/10/CytoSorbents-Investor-Present andy55q 10/18/17 09:28:32 AM
#10057   The company highlighted their growth/profitability strategy on the techxen 10/18/17 09:02:06 AM
#10056   New October Investor Presentation.Nice berthabluefish1 10/18/17 08:40:27 AM
#10055   Case of the week 41/2017 andy55q 10/18/17 07:41:21 AM
#10054   Ping, this is why I think Fresenius are htcblue 10/18/17 01:08:12 AM
#10053   Fresenius Medical Care (FMC) started it off with ping_pow_princess 10/18/17 12:22:20 AM
#10052   Ping, that is very good information and a htcblue 10/18/17 12:03:07 AM
#10051   I note that certain activities late 2016 and ping_pow_princess 10/17/17 11:45:41 PM
#10050   I hear ya htc.I understand what you are berthabluefish1 10/17/17 05:37:58 PM
#10049   YEARS ???..That's why I'm praying for a buyout. htcblue 10/17/17 04:53:40 PM
#10048   agreed. most of us watch this stock Psuforlife 10/17/17 04:29:47 PM
#10047   Either way Dr Chan is gonna be Dr. Good Sport 10/17/17 04:18:07 PM
#10046   I've given up thinking Dr. Chan can move htcblue 10/17/17 03:55:10 PM
#10045   Whats to post? Up a nickel, down coldterdinvestor 10/17/17 03:16:36 PM
#10044   It is amazing, no posts at all. Stock mikesmith999945 10/17/17 02:41:09 PM
#10043   The team found that fever of 102 and berthabluefish1 10/14/17 11:24:20 AM
#10042   http://www.fiercebiotech.com/research/averting-toxic-side-effects-from-car-t-can andy55q 10/14/17 09:14:24 AM
#10041   New Article.Averting Toxic Side Effects From Cart T berthabluefish1 10/13/17 10:58:27 PM
#10040   Pears', it gets olde, dude. Murph1953 10/13/17 05:28:27 PM
#10039   We don't know if Fresenius has sold a coldterdinvestor 10/13/17 04:44:13 PM
#10038   Pearsby, you post this on a monthly basis. biotech48 10/13/17 04:30:57 PM
#10037   Hoping that Fresenius will make a difference for berthabluefish1 10/13/17 03:48:57 PM
#10036   Still waiting on a Large Scale Multi Centered pearsby09 10/13/17 01:52:47 PM
#10035   Sepsis & septic shock market to be worth Early-One 10/13/17 08:32:04 AM
#10034   Waiting for Dr. Chan Oct 17th and 18th........ mikesmith999945 10/13/17 08:12:51 AM
#10033   What happened, everyone quit posting ml24 10/13/17 06:20:38 AM
#10032   All three videos been impressive, the German Fella mikesmith999945 10/10/17 09:29:10 PM
#10031   Just get a survivor on Dr Oz... HadToHavit 10/10/17 09:21:12 PM
PostSubject